A detailed history of American Portfolios Advisors transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, American Portfolios Advisors holds 500 shares of AVDL stock, worth $5,115. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Holding current value
$5,115
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$2.57 - $7.31 $1,285 - $3,655
500 New
500 $2.51 Million

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $620M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.